Aprepitant — Discount Pricing

Other medications in Oncology Support

• Darbepoetin Alfa
• Fosaprepitant
• Ondansetron ODT
• Palonosetron

About Aprepitant

Aprepitant is a powerful medication primarily used to prevent the debilitating nausea and vomiting associated with chemotherapy and surgery. Facing such treatments is challenging enough without the added worry of high prescription costs. TheDrugClub understands this need, offering prescription savings that can make accessing aprepitant more manageable for our members.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Aprepitant is approved for (FDA label)

Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist. Aprepitant capsules are indicated • in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: o acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1.1 ) o nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1.1 ) • for prevention of postoperative nausea and vomiting (PONV) in adults ( 1.2 ) Limitations of Use : ( 1.3 ) • Aprepitant has not been studied for treatment of established nausea and vomiting.

Source: Read the full FDA label on DailyMed. Label effective date: June 11, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Aprepitant (FDA label)

Aprepitant capsules, USP: • 40 mg: white body and yellow cap with "40 mg" printed in black ink on the body. • 80 mg: white body and white cap with "80 mg" printed in black ink on the body. • 125 mg: white body and pink cap with "125 mg" printed in black ink on the body. Aprepitant capsules, USP: 40 mg; 80 mg; 125 mg ( 3 ).

Source: FDA prescribing information (DailyMed). Set ID: af9b6086-4bf2-472c-8740-4134eaaebace. SPL document ID: d61cf041-fb75-4b56-949d-1f2f93acf4d0. Label effective date: June 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Aprepitant (FDA label)

Most common adverse reactions (≥3%) are ( 6.1 ): Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) • Adults: fatigue, diarrhea, asthenia, dyspepsia, abdominal pain, hiccups, white blood cell count decreased, dehydration, and alanine aminotransferase increased. • Pediatrics: neutropenia, headache, diarrhea, decreased appetite, cough, fatigue, hemoglobin decreased, dizziness, and hiccups. PONV • Adults: constipation and hypotension. To report SUSPECTED ADVERSE REACTIONS, contact Torrent Pharma Inc. at 1-800-912-9561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: af9b6086-4bf2-472c-8740-4134eaaebace. SPL document ID: d61cf041-fb75-4b56-949d-1f2f93acf4d0. Label effective date: June 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Aprepitant (FDA label)

Aprepitant is contraindicated in patients: • who are hypersensitive to any component of the product. Hypersensitivity reactions including anaphylactic reactions have been reported [see Adverse Reactions ( 6.2 )] . • taking pimozide. Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of this drug which is a CYP3A4 substrate, potentially causing serious or life-threatening reactions, such as QT prolongation, a known adverse reaction of pimozide [see Warnings and Precautions ( 5.1 )] . • Known hypersensitivity to any component of this drug. ( 4 ) • Concurrent use with pimozide. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: af9b6086-4bf2-472c-8740-4134eaaebace. SPL document ID: d61cf041-fb75-4b56-949d-1f2f93acf4d0. Label effective date: June 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Aprepitant (FDA label)

• CYP3A4 Interactions : Aprepitant is a substrate, weak-to-moderate inhibitor and inducer of CYP3A4; See Full Prescribing Information for recommendations regarding contraindications, risk of adverse reactions, and dosage adjustments of aprepitant and concomitant drugs. ( 4 , 5.1 , 7.1 , 7.2 ) • Warfarin (a CYP2C9 substrate) : Risk of decreased INR of prothrombin time; monitor INR in 2-week period, particularly at 7 to 10 days, following initiation of aprepitant. ( 5.2 , 7.1 ) • Hormonal Contraceptives : Efficacy of contraceptives may be reduced during administration of and for 28 days following the last dose of aprepitant.

Source: FDA prescribing information (DailyMed). Set ID: af9b6086-4bf2-472c-8740-4134eaaebace. SPL document ID: d61cf041-fb75-4b56-949d-1f2f93acf4d0. Label effective date: June 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Aprepitant (FDA label)

See Full Prescribing Information for a list of clinically significant drug interactions. ( 4 , 5.1 , 5.2 , 5.3 , 7.1 , 7.2 ) 7.1 Effect of Aprepitant on the Pharmacokinetics of Other Drugs Aprepitant is a substrate, a weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. Aprepitant is also an inducer of CYP2C9 [see Clinical Pharmacology ( 12.3 )] . Aprepitant acts as a moderate inhibitor of CYP3A4 when administered as a 3-day regimen (125mg/80-mg/80-mg) and can increase plasma concentrations of concomitant drugs that are substrates for CYP3A4. Aprepitant acts as a weak inhibitor when administered as a single 40-mg dose and has not been shown to alter the plasma concentrations of concomitant drugs that are primarily metabolized through CYP3A4. Some substrates of CYP3A4 are contraindicated with aprepitant [see Contraindications ( 4 )] . Dosage adjustment of some CYP3A4 and CYP2C9 substrates may be warranted, as shown in

Source: FDA prescribing information (DailyMed). Set ID: af9b6086-4bf2-472c-8740-4134eaaebace. SPL document ID: d61cf041-fb75-4b56-949d-1f2f93acf4d0. Label effective date: June 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.